Overview

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
0
Participant gender:
All
Summary
To compare side effects and complications relating to use of warfarin or rivaroxaban, tolerance and/or toxicity of these two agents such as drop in hemoglobin post operatively, extent of bruising, quantity of wound drainage, duration of drainage, wound swelling, sub and supra-therapeutic prothrombin times, need for transfusion, and patient tolerance in two randomized groups. Return visits to the operating room, length of stay, and VTE rates will also be compared.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Michigan
Treatments:
Rivaroxaban
Warfarin
Criteria
Inclusion Criteria:

- All patients over the age of 18 undergoing primary hip or knee replacement by Dr.
Urquhart or Dr. Hallstrom.

Exclusion Criteria:

- Patients with a contraindication to pharmacologic VTE prophylaxis such as hemophilia,
Plavix use, active bleeding or prior reaction to warfarin or rivaroxaban, nursing
mothers, hepatic disease, GFR <30, use of more than 200mg of aspirin daily, and
inability to continue medication or lab monitoring after hospital discharge known
preoperatively.